Cytokinetics Inc CYTK said on Friday it had stopped a late-study stage of its treatment for amyotrophic lateral sclerosis (ALS), as the drug was found to be ineffective.
Bu haberi okumak için giriş yapın veya sonsuza kadar ücretsiz bir hesap oluşturun